Neurofeedback for Attention-Deficit/Hyperactivity Disorder: 25-Month Follow-up of Double-Blind Randomized Controlled Trial - 28/03/23
Abstract |
Objective |
To examine delayed effects of theta-beta ratio (TBR) neurofeedback (NF) for attention-deficit/hyperactivity disorder (ADHD) 25 months after baseline, ∼21 months after end of treatment.
Method |
Children aged 7 to 10 years with rigorously diagnosed ADHD had been randomized to 38 sessions of TBR NF (n = 84) or control treatment (n = 58) of identical appearance, intensity/frequency, and duration, differing only in that reinforcement for controls was based on a pre-recorded electroencephalogram (EEG) of another child. Child, parent, and all site staff were blinded until after 25-month assessments, with only one-fourth able to guess the control treatment correctly. Baseline assessments were repeated off medication after 25 months.
Results |
Of the 142 participants, 120 had 25-month follow-up (84.5% retention). Only 12 participants (6 controls) had NF after the study treatment, greatly retaining the randomization. The primary outcome, parent-rated inattention, was not significantly different between treatments despite large pre−post effect sizes (NF recipients, d = 1.63; controls, d = 1.42). Most secondary measures showed the same pattern. Response rates (Clinical Global Impression−Improvement ≤2) were 58.6% of NF recipients and 66% of controls (not significant). Marginally more controls than NF recipients needed medication (57.1% vs 38.6%, p = .059); specifically, 7.1% of NF recipients and 4% of controls had reduced medication need, whereas 34.3% of NF recipients and 50% of controls needed more medication (p = 0.084).
Conclusion |
Most of the large within-group improvement from the NF treatment package reported by unblinded studies and replicated in this blinded study reflects nonspecific effects, not specific effects of deliberate down-training of EEG theta-beta power ratio. At 25-month follow-up, it appears comparable to the evidence-based Multimodal Treatment Study of ADHD (MTA) treatments, suggesting a psychotherapeutic/behavioral effect.
Clinical trial registration information |
Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD; clinicaltrials.gov/; NCT02251743.
Diversity & Inclusion Statement |
We worked to ensure sex and gender balance in the recruitment of human participants. We worked to ensure race, ethnic, and/or other types of diversity in the recruitment of human participants. We worked to ensure that the study questionnaires were prepared in an inclusive way. One or more of the authors of this paper self-identifies as a member of one or more historically underrepresented sexual and/or gender groups in science. We actively worked to promote sex and gender balance in our author group.
Le texte complet de cet article est disponible en PDF.Key words : ADHD, neurofeedback, double-blind randomized clinical trial, long-term follow-up, EEG biofeedback
Plan
| This research was supported by the National Institute of Mental Health grant #R01-MH100144, the National Center for Translational Sciences award #8UL18TR000090-05, and by the Ohio State University College of Medicine Endowment. |
|
| The research was performed with permission from the Buck Institutional Review Board. |
|
| Xueliang (Jeff) Pan, PhD, of Ohio State University, Helena C. Kraemer, PhD, of Stanford University, and Yubo Tan, MS, of Ohio State University, served as the statistical experts for this research. |
|
| Authors of this article comprise the Neurofeedback Collaborative Group, listed in alphabetical order (not necessarily order of contribution): L. Eugene Arnold, MD, MEd, Martijn Arns, PhD, Justin A. Barterian, PhD, Shea Connor, BS, Roger J. deBeus, PhD, Jill A. Hollway, PhD, MA, Cynthia Kerson, PhD, Howard Lightstone, BS, Joel F. Lubar, PhD, Keith McBurnett, PhD, Vincent J. Monastra, PhD, Arielle Mulligan, BS, Kristin Buchan-Page, BA, Xueliang (Jeff) Pan, PhD, Robert Rice, Jr. PhD, Michelle E. Roley-Roberts, PhD, Constance A. Schrader, PhD, Yubo Tan, MS, Craig Williams, MD |
|
| Disclosure: Dr. Arnold has received research funding from Curemark, Forest, Lilly, Neuropharm, Novartis, Noven, Otsuka, Roche/Genentech, Shire, Supernus, Axial, and Yamo (as well as NIH and Autism Speaks), has consulted with CHADD, Neuropharm, Organon, Pfizer, Sigma Tau, Shire, Tris Pharma, and Waypoint, and has been on advisory boards for Arbor, Ironshore, Novartis, Noven, Otsuka, Pfizer, Roche, Seaside Therapeutics, Sigma Tau, and Shire. Dr. Arns has been an unpaid chairman of the non-profit Brainclinics Foundation, a minority shareholder in neuroCare Group (Munich, Germany), and a co-inventor on 4 patent applications related to EEG, neuromodulation and psychophysiology, but has received no royalties related to these patents; Research Institute Brainclinics received research funding from neuroCare Group (Munich, Germany), Brain Resource (Sydney, Australia), Urgotech (France), Brainify (US) and equipment support from Deymed, neuroConn, Compumedics, and Magventure. Dr. Barterian has received royalties from Springer. Dr. deBeus has a private clinic using neurofeedback. Dr. Monastra has a private clinic using neurofeedback. Drs. Hollway, Kerson, Lubar, McBurnett, Pan, Rice, Roley-Roberts, Schrader, and Williams, Ms. Connor, Mr. Lightstone, Ms. Mulligan, Ms. Buchan-Page, and Mr. Tan have reported no biomedical financial interests or potential conflicts of interest. |
|
| Correspondence to L. Eugene Arnold, MD, MEd, Professor Emeritus of Psychiatry and Behavioral Health, Ohio State University, 1581 Dodd Drive, Columbus, OH 43210; e-mail: L.Arnold@osumc.edu |
Vol 62 - N° 4
P. 435-446 - avril 2023 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
